These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

55 related articles for article (PubMed ID: 2555960)

  • 1. [Sodium transport inhibitor in hypertensives].
    Shul'ga IuD; Berezniakov IG
    Vrach Delo; 1989 Aug; (8):1-3. PubMed ID: 2555960
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Individual variability in membrane sodium transport during salt loading--evidence against the production of a Na+-K+-ATPase inhibitor in hypertension.
    Maling TJ; Siebers RW
    Prog Biochem Pharmacol; 1988; 23():91-100. PubMed ID: 2847194
    [No Abstract]   [Full Text] [Related]  

  • 3. [Natraemia, natriuresis, inhibitors of sodium transport and high blood pressure].
    de Wardener H
    Nephrol Ther; 2007 Dec; 3(7):433-6. PubMed ID: 18047997
    [No Abstract]   [Full Text] [Related]  

  • 4. [Transmembrane Na+ transport kinetics in arterial hypertension: relations with vascular risk parameters].
    Caballero Oliver A; Stiefel García-Junco P; García-Donas López MA; Villar Ortiz J; Carneado de la Fuente J
    Med Clin (Barc); 1995 Dec; 105(20):768-73. PubMed ID: 8558976
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endogenous Na+ transport inhibitor in human hypertension: further biochemical and chemical studies.
    Cloix JF; Crabos M; Grichois ML; Guicheney P; Meyer P
    Klin Wochenschr; 1987; 65 Suppl 8():146-53. PubMed ID: 3037183
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lymphocyte sodium efflux in normotensive and borderline hypertensive subjects with and without heredity for hypertension.
    Pedersen KE; Nielsen JR; Klitgaard NA; Jest P; Johansen T
    Scand J Clin Lab Invest Suppl; 1986; 180():101-3. PubMed ID: 3012759
    [No Abstract]   [Full Text] [Related]  

  • 7. Chemical, experimental, and clinical studies on endogenous ouabain-like substance in hypertension.
    Cloix JF; Crabos M; Devynck MA; Elghozi JL; Henning G; Kamal LA; Lacerda-Jacomini LC; Meyer P; Pernollet MG; Rosenfeld JB
    Adv Nephrol Necker Hosp; 1985; 14():161-71. PubMed ID: 2579533
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Membrane transport of ions in hypertension: a review.
    Heagerty AM; Riozzi A; Brand SC; Bing RF; Thurston H; Swales JD
    Scand J Clin Lab Invest Suppl; 1986; 180():54-64. PubMed ID: 3012763
    [No Abstract]   [Full Text] [Related]  

  • 9. Raised sodium pump activity and a circulating sodium transport inhibitor demonstrated on red blood cells of patients with untreated essential hypertension: correlation of pump activity with potassium permeability.
    Skrabal F; Hamberger L; Cerny E; Schönegger J; Gernhold M
    Klin Wochenschr; 1985; 63 Suppl 3():117-21. PubMed ID: 2987607
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sodium transport inhibitors.
    Prog Biochem Pharmacol; 1988; 23():1-161. PubMed ID: 2847180
    [No Abstract]   [Full Text] [Related]  

  • 11. Recent progress on an endogenous digitalislike factor in hypertension.
    Cloix JF; Crabos M; Meyer P
    J Clin Hypertens; 1986 Jun; 2(2):93-100. PubMed ID: 3020179
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dietary salt, intracellular ion homeostasis and hypertension secondary to early-stage kidney disease.
    Schiffl H; Küchle C; Lang S
    Miner Electrolyte Metab; 1996; 22(1-3):178-81. PubMed ID: 8676814
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Circulating inhibitor of the Na+-K+ pump in essential hypertension. Physiological and pharmacological variations].
    Pernollet MG; de Thé H; Delva P; Wauquier I; Devynck MA; Baudouin-Legros M; Deray G; Rosenfeld J; Meyer P
    Arch Mal Coeur Vaiss; 1984 Oct; 77(11):1283-7. PubMed ID: 6098238
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Erythrocyte sodium and Na+, K(+)-ATPase activity in untreated hypertensives and their first degree relatives.
    Sudhakar K; Sujatha M; Devi CV; Reddy PP
    Indian J Biochem Biophys; 1998 Dec; 35(6):382-4. PubMed ID: 10412234
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Cytochemical demonstration of an endogenous inhibitor of Na-K ATPase and its relationship to familial arterial hypertension].
    de Wardener H
    Nephrologie; 1987; 8(1):3-6. PubMed ID: 3035398
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Central hemodynamic function and the metabolic electrolyte ratio of patients with hypertension and hereditary disposition].
    Kharchenko VI; Liusov VA; Petraneva EV; Evsikov EM; Postnov IIu
    Ter Arkh; 1985; 57(9):43-9. PubMed ID: 3909479
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Circulating inhibitor of sodium active transport in essential hypertension and volemic expansion].
    Devynck MA; Pernollet MG; Deray G; Rieu M; Meyer P
    Arch Mal Coeur Vaiss; 1985 Oct; 78(11):1691-5. PubMed ID: 3006621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The relation of the natriuretic hormone to essential hypertension.
    de Wardener HE; MacGregor GA
    Postgrad Med J; 1983; 59 Suppl 2():74-7. PubMed ID: 6310538
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A circulating sodium transport inhibitor and essential hypertension.
    MacGregor GA; de Wardener HE
    J Cardiovasc Pharmacol; 1984; 6 Suppl 1():S55-60. PubMed ID: 6204160
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical profile of essential hypertensives based on ion transport abnormalities.
    de la Sierra A; Coca A; Paré JC; Sánchez M; Compte M; Azqueta M; Urbano-Márquez A
    J Hypertens Suppl; 1993 Dec; 11(5):S250-1. PubMed ID: 8158369
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.